Anzeige
Meldung des Tages: Die nächsten 10.000 Bohrmeter könnten alles verändern, während andere Explorer noch planen

Camden Property Trust News

Aktie
WKN:  985335 ISIN:  US1331311027 US-Symbol:  CPT Branche:  Immobiliengesellschaften (REITs) Land:  USA
101,84 $
+0,00 $
0,00%
88,265 € 12.03.26
Depot/Watchlist
Marktkapitalisierung *
9,90 Mrd. €
Streubesitz
-
KGV
96,53
Dividende
3,65 EUR
Dividendenrendite
3,97%
Nachhaltigkeits-Score
38 %
Index-Zuordnung
S&P 500

Camden Property Trust News

17.02.26 - PR Newswire
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-​Loss Treatments PR Newswire
26.11.25 - PR Newswire
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire
20.10.25 - PR Newswire
CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
CollPlant's rhCollagen-​Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology PR Newswire
16.10.25 - PR Newswire
First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
First-​in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-​Based BioInk PR Newswire
30.09.25 - PR Newswire
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler
CollPlant Biotechnologies Announces Positive Results from non-​clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler PR Newswire
15.09.25 - PR Newswire
CollPlant Expands the Distribution of its VergenixSTR Product in Europe
CollPlant Expands the Distribution of its VergenixSTR Product in Europe PR Newswire
02.09.25 - PR Newswire
CollPlant to Present at the 2025 International Conference on Biofabrication
CollPlant to Present at the 2025 International Conference on Biofabrication PR Newswire
25.08.25 - PR Newswire
CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference PR Newswire
20.08.25 - PR Newswire
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire
05.08.25 - PR Newswire
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS PR Newswire
09.06.25 - PR Newswire
COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES PR Newswire
04.06.25 - PR Newswire
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-​BASED FORMULATIONS USABLE AS SOFT TISSUE ...
14.05.25 - PR Newswire
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS PR Newswire
15.04.25 - PR Newswire
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies PR Newswire

Newssuche

Videos

newspaper
10.03.26 -10,03%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »